Allergan (AGN) Enters agreement to Acquire Naurex in Net $560M Deal

Go back to Allergan (AGN) Enters agreement to Acquire Naurex in Net $560M Deal

Canaccord Genuity Raises Price Target on Allergan (AGN) Following Announced Generics Sale

July 28, 2015 9:13 AM EDT

Canaccord Genuity reiterated a Buy rating on Allergen (NYSE: AGN), and raised the price target to $396.00 (from $352.00), following the announced sale of its generics unit to Teva (NYSE: TEVA). Teva will acquire the unit for $40.5B.... More

Leerink Partners Raised Price Target on Allergan (AGN) to $388 Following TEVA Announcement

July 28, 2015 8:19 AM EDT

Allergan (NYSE: AGN)
Leerink Partners reiterated an Outperform rating on Allergen (NYSE: AGN), and raised the price target to $388.00 (from $354.00), following this morning's announcement that TEVA will be acquiring AGNs Gx biz for $40.5B. Analyst Jason Gerberry views TEVA (OP) as the most suitable owner for the AGN's Gx assets.

Gerberry... More

Teva Pharma (TEVA) Nears Deal to Acquire Allergan's (AGN) Generic-Drug Business

July 26, 2015 5:23 PM EDT

Israel-based drug maker Teva Pharma (NYSE: TEVA) is in talks to acquire Allergan's (NYSE: AGN) generic-drug business, the Wall Street Journal reported on Saturday. The deal is said to be valued at about $45 billion and could be announced as soon as Monday.

If a deal is... More